tbuckley/cabot-search huggingface dataset:
Treatment of Life-Threatening Infantile Hemangiomas with Vincristine
Authors: Jaime Perez Payarols, Jose Pardo Masferrer, Cristina Gomez Bellvert
Journal: New England Journal of Medicine (1995)

To the Editor: We describe two cases of corticosteroid-resistant, life-endangering hemangioma treated with vincristine: a benign hemangioendothelioma in a patient with Kasabach-Merritt syndrome and a liver hemangioendothelioma. Mortality rates among patients with these kinds of hemangioma can be as high as 40 percent and may be more than 50 percent if poor prognostic factors are present.1,2 Corticosteroids are the medical treatment of choice, except for resistant cases,3 which are not infrequent. The first patient was a nine-month-old baby who presented with a tumor 10 cm in diameter in the left supraclavicular region and a platelet count of 7400 per . . .
AB1109 Joint involvement in mucopolysaccharidosis first diagnosed as legg-calvΈ-perthes disease
Authors: A. Sόlyom, K. Komlόsi, G. Mohay, Z. Nyul
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Early joint involvement in certain types of mucopolysaccharidoses (MPS) can lead to initial referral to a pediatric rheumatologist or orthopedic surgeon because of suspicion of juvenile idiopathic arthritis or other joint disease [1]. We document here the case of a male patient who was treated for Legg-Calvé-Perthes Disease of the right hip at an orthopedic center at 3 years of age after presenting with a limp, and who was subsequently diagnosed with mucopolysaccharidosis II (Hunter Syndrome) 18 months later. <h3>Objectives</h3> We hope to highlight the significance of joint involvement in the disease course of a young MPS patient, and relate an example of the often complicated route to a final diagnosis in the various attenuated forms of MPS. <h3>Results</h3> Upon the patient's arrival at our department, only a slight limp was apparent, which did not significantly affect the everyday life of the active 5 year old. An X-ray examination showed pronounced degenerative changes in both hips. Subsequent review of the hip X-ray performed at the age of 3 years revealed relatively minor changes in the left femoral head with involvement of the acetabulum bilaterally, in addition to the damage originally noted in the right femoral head. His urinary glycosaminoglycan (GAG) concentration was pathologically elevated (220 mg/g creatinine, norm: &lt;60mg/g), including abnormal fractions of dermatan and heparan sulfate, and the iduronate-2-sulfatase (IDS) enzyme activity was close to zero. Genetic testing revealed an as yet unpublished missense mutation in the iduronate sulfatase gene. The physical features of MPS II, including joint contractures, dysostosis multiplex, coarse facies, hepatomegaly and umbilical hernia are recognizable in our patient, but there is no sign of central nervous system involvement. Enzyme replacement therapy (ERT) with idursulfase (Elaprase) was started in May, 2011. <h3>Conclusions</h3> Through the presentation of this case we hope to encourage the inclusion of mucopolysaccharidosis and other lysosomal storage diseases, when appropriate, in the differential diagnostic spectrum of cases of joint disease which is atypical, or in cases where the etiology is uncertain. <h3>References</h3> Cimaz, R., et al., Joint contractures in the absence of inflammation may indicate Mucopolysaccharidosis. Pediatric Rheumatology, 2009, 7:18. <h3>Disclosure of Interest</h3> None Declared
Single-port transgastric access for repeated debridement of infected pancreatic necrotic tissue
Authors: J. Kobiela, S. Hac, Z. Sledzinski
Journal: Endoscopy (2010)

We present a novel technique developed in our institution: repeated single-port transgastric debridement of walled-off pancreatic necrotic tissue using TriPort Access System (Olympus, Warsaw, Poland).
Jehovah's Witnesses and Blood Transfusions
Authors: Edwin J. Holman
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
678 18F-FLUORO-DEOXYGLUCOSE PET/CT PREDICTS TUMOR PROGRESSION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA TREATED WITH LOCOREGIONAL TREATMENT
Authors: M. Song, S.H. Bae, J.Y. Choi, S.K. Yoon, S.H. Jo, J.Y. Han, N.I. Han, S.W. Choi, Y.S. Lee, C.D. Lee
Journal: Journal of Hepatology (2013)
Contribution of an Anti-CEA Fab’ Scan in the Detection of Medullary Thyroid Cancer
Authors: Julia Malamitsi, Paris A Kosmidis, Savvas Papadopoulos, Andreas Petounis, Dimitrios A Linos
Journal: Clinical Nuclear Medicine (2002)

MALAMITSI, JULIA M.D. M.Sc.,*; KOSMIDIS, PARIS A. M.D.,‡; PAPADOPOULOS, SAVVAS M.D.,§; PETOUNIS, ANDREAS M.D.†; LINOS, DIMITRIOS A. M.D., F.A.C.S.∥ Author Information
CBIO-25NEW HYPOXIA-INDUCED INVASION FACTOR IN HUMAN GLIOBLASTOMA INVASION
Authors: Hiroyuki Michiue, Atsushi Fujimura, Hiroaki Mastushita, Tei-ichi Nishiki, Hideki Matsui
Journal: Neuro-Oncology (2015)

Microenvironmental conditions such as hypoxia potentiate the local invasion of malignant tumors including glioblastomas by modulating signal transduction and protein modification, yet the mechanism by which hypoxia controls cytoskeletal dynamics to promote the local invasion is not well defined. Here, we show that cyclin G2 plays pivotal roles in the cytoskeletal dynamics in hypoxia-driven invasion by glioblastoma cells. Cyclin G2 is a hypoxia-induced and cytoskeleton-associated protein and is required for glioblastoma expansion. Mechanistically, cyclin G2 recruits cortactin to the juxtamembrane through its SH3 domain-binding motif and consequently promotes the restricted tyrosine phosphorylation of cortactin in concert with src. Moreover, cyclin G2 interacts with filamentous actin to facilitate the formation of membrane ruffles. In primary glioblastoma, cyclin G2 is abundantly expressed in severely hypoxic regions such as pseudopalisades, which consist of actively migrating glioma cells. Furthermore, we show the effectiveness of dasatinib against hypoxia-driven, cyclin G2-involved invasion in vitro and in vivo. Our findings elucidate the mechanism of cytoskeletal regulation by which severe hypoxia promotes the local invasion and may provide a therapeutic target in glioblastoma.
AB0370 An open label trial assessing the efficacy of mycophenolate sodium in active systemic lupus erythematosus patients without renal impairment
Authors: F. Yahya, R. Jasmin, T. E. Cheah, C. T. Ng, S. Sockalingam
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease which is associated with a wide range of clinical, immunological and haematological manifestations. There is an inflammatory response which involves a number of auto antibodies directed at self antigens. The use of mycophenolate is currently becoming more widely used in the treatment of SLE.(1-3) Due to paucity of data in using mycophenolate sodium in SLE, we designed a prospective study to assess the efficacy and safety of this medication in active SLE patients without renal involvement (non-renal SLE). <h3>Objectives</h3> This study aimed to assess the efficacy of mycophenolate sodium in active SLE patients without renal involvement. <h3>Methods</h3> A total of 14 active SLE patients without renal involvement were randomised either to receive mycophenolate sodium or other immunosuppressive agents. Patients were assessed monthly from baseline until week 16. Assessment parameters included SLE Disease Activity Score (SLEDAI) score, other organ specific parameters and immunological parameters including anti-dsDNA and C3. Steroid-sparing effect of mycophenolate sodium was also evaluated. <h3>Results</h3> Mycophenolate sodium had a significant reduction in SLEDAI scores (<i>p</i>&lt;0.05) after 16 weeks of treatment. Mixed responses were detected in terms of organ-specific clinical changes. A positive trend was observed in improvement of immunological parameters and steroid dose reduction. However, both of these results were not statistically significant. No major adverse events were reported in the study. <h3>Conclusions</h3> In conclusion, mycophenolate sodium can be considered as a safe alternative immunosuppressant in the treatment of SLE with extra renal manifestations. Due to the limitations in the study, a larger prospective study should be performed to explore its efficacy in SLE. <h3>References</h3> Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss medical weekly. 2009;139(3-4):41-6. Epub 2009/01/27. Fine DM. Pharmacological therapy of lupus nephritis. JAMA : the journal of the American Medical Association. 2005;293(24):3053-60. Epub 2005/06/24. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus. 1999;8(9):731-6. Epub 1999/12/22. <h3>Acknowledgements</h3> We would like to thank Novartis for supplying the medications and other healthcare staff who were involved in this study. <h3>Disclosure of Interest</h3> F. Yahya Grant/research support from: Novartis, R. Jasmin Grant/research support from: Novartis, T. E. Cheah Grant/research support from: Novartis, C. T. Ng Grant/research support from: Novartis, S. Sockalingam Grant/research support from: Novartis
FRI0377 Early response to treatment is a surrogate marker of flare recurrence in acute gouty arthritis
Authors: A. So, T. Bardin, M. Bloch, A. Shpilsky, T. Kiechle, N. Schlesinger
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Canakinumab, a fully human anti-IL-1β monoclonal antibody, selectively targets IL-1β and may be an alternative treatment to NSAIDs or colchicine in patients (pts) presenting with acute gouty arthritis (GA), in whom standard care is inappropriate or ineffective. The ideal qualities of such a treatment should include fast and potent pain relief and reduction of the risk of a new flare. When treating pts with biologic therapy, it is important to develop criteria for response-guided retreatment decisions to reduce risk of futile treatment and potential exposure to an unnecessary safety risk. <h3>Objectives</h3> To explore the rapidity of response to treatment, defined as ≥50% pain reduction within 7 days, as a potential surrogate marker of time to new flare. <h3>Methods</h3> A good concordance between prevention of flare and 50% pain reduction on a 0-100 mm visual analogue scale (VAS) was detected in a retrospective pooled analysis of two 12-week studies (β-RELIEVED, N=230; β-RELIEVED-II, N=226) in pts treated with a single dose of canakinumab 150mg sc or triamcinolone acetonide (TA) 40 mg im. The 12-week extension studies allowed evaluation of early pain response as a predictor of delay to new flare. The predictive value of the response was studied using a Cox model with response as a time-dependent covariate and the number of flares in the previous year as baseline predictor. <h3>Results</h3> 50% pain reduction within 7 days of treatment was confirmed to be a highly significant predictor of time to new flare (p&lt;0.0001). The hazard ratio for responders vs non-responders was 0.47 (95% CI, 0.32 – 0.67). The baseline number of flares was also significant (p=0.0011) confirming the temporal aspect of disease severity as intensity of recurrent disease. A similar result was obtained for time from response (or Day 7 for non-responders) to new flare using Kaplan-Meier technique (log-rank test, p&lt;0.0001) with median time 100 days for non-responder and non-estimable yet for responders within 6 month study (Figure). <h3>Conclusions</h3> These results demonstrate that a 50% pain reduction by VAS within 7 days of treatment in acute GA pts is associated with delay of new flare and can be used as a surrogate marker of time to new flare. <h3>Disclosure of Interest</h3> A. So Grant/Research support from: Novartis, Consultant for: Novartis, Ardea, Speakers Bureau: Novartis, Ardea, Menarini, T. Bardin Grant/Research support from: Menarini, Consultant for: Novartis, Ipsen, Menarini, Ardea, Biocryst, M. Bloch Grant/Research support from: Novartis, A. Shpilsky Shareholder of: Novartis, Employee of: Novartis, T. Kiechle Shareholder of: Novartis, Employee of: Novartis, N. Schlesinger Grant/Research support from: Novartis, Consultant for: Novartis, URL Pharma, Savient, Takeda, Rx Ensyme, Speakers Bureau: Takeda, Savient, Novartis
Nevus Unius Lateralis
Authors: Norman Lenson
Journal: New England Journal of Medicine (1953)

NEVUS unius lateralis is a unique clinicopathologic entity, characterized by a congenital papillary growth that is predominantly unilateral and linear in distribution. Pack and Sunderland1 have presented an excellent review of the subject, noting the myriad of synonyms for nevus unius lateralis, and have added 4 cases to the literature, to make a total of 160 reported cases. I have been unable to find any case report in the literature since 1941, nor have any of the cases pieviously reported presented the unique association with congenital abnormalities demonstrated in the case described below.Other congenital abnormalities have been reported with . . .
The dual nature of tools and their makeover
Authors: Antonio Rizzo
Journal: Behavioral and Brain Sciences (2012)

Abstract Vaesen argues that functional knowledge differentiates humans from non-human primates. However, the rationale he provides for this position is open to question – with respect to both the underlying theoretical assumptions and inferences drawn from certain empirical studies. Indeed, there is some recent empirical work that suggests that functional fixedness is not necessarily uniquely human. I also question the central role of stable function representations in Vaesen's account of tool production and use.
Abstract 2925: Protein pathway activation mapping of the NCI60 cell line series: Discovery of lineage-independent protein biomarkers for drug sensitivity/resistance prediction
Authors: Giulia Federici, Valentina Fodale, Jianghong Deng, Ruggero De Maria, Lance A. Liotta, Emanuel F. Petricoin, Julia D. Wulfkuhle
Journal: Cancer Research (2011)

Abstract The NCI-60 cell lines are a set of human tumor cell lines derived from different organ sites including brain, blood and bone marrow, breast, colon, kidney, lung, ovary, prostate and skin. These cell lines have been characterized through genetic screening, such as chromosome karyotyping, gene expression analysis, protein expression and sequencing and are likely the most well-characterized cell lines in the world. Through the use of Reverse-Phase Protein Microarrays (RPMA) we performed an in-depth analysis of signal pathway activation, measuring the activation state of nearly 200 key signaling proteins representative of pathways involved in proliferation, survival, inflammation, adhesion, and migration. This broad-based screening allowed the characterization of activated intracellular signaling pathways and identified 11 clear subclasses based on molecular architectures which transcended cell line lineage. Statistical analysis of signaling architecture of the most drug-resistant and sensitive lines, defined by publicly available GI50 data was performed for a number of molecularly targeted-therapeutics. We identified novel and previously known protein biomarkers that correlated with resistance and sensitivity to these inhibitors, which indicated the potential for functional signaling analysis of the cell lines to produce biomarkers that could be useful in vivo if extensively validated. Our goal is to be able to assign a specific protein signaling architecture for each specific drug sensitivity profile such that predictive markers can emerge in a biochemically-driven fashion. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2925. doi:10.1158/1538-7445.AM2011-2925
402P Efficacy of duloxetine for paclitaxel-induced and pregabalin-resistant peripheral neuropathy in Japanese breast cancer patients
Authors: K. Yamada, H. Kaise, M. Hosonaga, F. Kimura, Y. Kawai, A. Ueda, S. Teraoka, M. Okazaki, T. Ishikawa
Journal: Annals of Oncology (2015)
SAT0596-HPR Thumb Base Involvement in Established Hand Osteoarthritis
Authors: C. Van Den Ende, M. Stukstette, J. Dekker, D.-J. De Rooij, M. Kloppenburg, J. W. Bijlsma
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To explore the association between radiographic and clinical involvement of the thumb base joint with patient and disease characteristics and with pain and limitations in activities in hand osteoarthritis (OA). <h3>Methods</h3> Baseline data of 151 patients with hand OA participating in a randomized clinical trial on the effectiveness of a multidisciplinary treatment program was used. Clinical involvement of the thumb base joint was defined as tenderness at palpation in at least one thumb base joint whereas radiological involvement was defined as Kellgren and Lawrence score ≥ 2 in at least one thumb base joint. Multivariable linear and logistic regression analyses were used, where appropriate, to estimate the independent association of clinical and radiological thumb base joint involvement as independent variables with patient and disease characteristics, hand functions and activities, psychosocial variables and health-related quality of life as dependent variables. <h3>Results: </h3> In 38% (n=58) of the patients (mean age 59.2 years, 83% female) ≥ 1 thumb base joint was tender on palpation whereas in 69% (93 out of 135 patients) ≥ 1 thumb base joints had K&amp;L score ≥2. 36% patients showed neither clinical nor radiological involvement, whereas 42% showed both clinical and radiological involvement of the thumb base joint. On joint level, the presence of radiological involvement of the thumb base joint showed a clear association with joint tenderness (odds ratio 5.4, 95% CI: 1.5 – 8.7). Clinical involvement of the thumb base joint was, adjusted for radiological involvement, associated with the number of tender hand joints (B (CI): 6.3 (4.2;8.4)), number of co morbidities (B(CI): 0.5 (0.0;1.0)), limitations in hand activities (Australian Canadian Osteoarthritis Hand Index) (B(CI): 4.0 (1.7;6.3)), passive coping strategies and pain (subscale "bodily pain" of the short form health survey (SF-36)) (B(CI): -6.8 (-12.8; -0.8)). Radiological involvement of the thumb base joint was, adjusted for clinical involvement, associated with age (B (CI): 4.8 (1.9; 7.7)), number of hand joints with K&amp;L score ≥2 (B (CI): 5.2 (2.8;7.8)) and presence of erosions (yes/no) (odds ratio (CI): 4.1(1.9;9.2)). <h3>Conclusions</h3> In patients with established hand OA clinical involvement of the thumb base is associated with a higher clinical burden whereas radiological involvement of the thumb base joints is associated with older age and more structural abnormalities. Our results imply that clinical involvement of the thumb base joint rather than radiological involvement should be a starting point for symptomatic treatment. An aberrant pain behavior style might underlie the expression of OA-related symptoms. <h3>Disclosure of Interest</h3> None Declared
Second-Pandemic Strain of<i>Vibrio cholerae</i>from the Philadelphia Cholera Outbreak of 1849
Authors: Alison M. Devault, G. Brian Golding, Nicholas Waglechner, Jacob M. Enk, Melanie Kuch, Joseph H. Tien, Mang Shi, David N. Fisman, Anna N. Dhody, Stephen Forrest, Kirsten I. Bos, David J.D. Earn, Edward C. Holmes, Hendrik N. Poinar
Journal: New England Journal of Medicine (2014)

In the 19th century, there were several major cholera pandemics in the Indian subcontinent, Europe, and North America. The causes of these outbreaks and the genomic strain identities remain a mystery. We used targeted high-throughput sequencing to reconstruct the Vibrio cholerae genome from the preserved intestine of a victim of the 1849 cholera outbreak in Philadelphia, part of the second cholera pandemic. This O1 biotype strain has 95 to 97% similarity with the classical O395 genome, differing by 203 single-nucleotide polymorphisms (SNPs), lacking three genomic islands, and probably having one or more tandem cholera toxin prophage (CTX) arrays, which potentially affected its virulence. This result highlights archived medical remains as a potential resource for investigations into the genomic origins of past pandemics.
Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma
Authors: John G. Gribben, Arnold S. Freedman, Donna Neuberg, Denis C. Roy, Kelly W. Blake, Sunhee D. Woo, Michael L. Grossbard, Susan N. Rabinowe, Felice Coral, Gordon J. Freeman, Jerome Ritz, Lee M. Nadler
Journal: New England Journal of Medicine (1991)

The use of autologous bone marrow transplantation is increasing in the management of advanced cancers. Many investigators have attempted to "purge" autologous marrow of residual tumor cells because of concern that reinfused tumor cells might contribute to relapse. The efficacy of purging remains unproved.